MeiraGTx Holdings plc Dossier - Source-backed chat

MeiraGTx Holdings plc

MGTXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.17

Intrinsic Value $9.93median of 4 methods · middle span $9-$10based on filings through 30 Jun 2026

Market Price $10.66Price as of 1 Oct 2026

Near fair valueIntrinsic value is 7% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $1B

Shares Outstanding 88.7M diluted

Next Earnings Date16 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

MeiraGTx is transitioning from a clinical-stage R&D biotech to a commercial-ready genetic medicines company. The strategic reacquisition of bota-vec from Johnson & Johnson, combined with Breakthrough Therapy designation for AAV2-hAQP1 and deep partnerships with Eli Lilly and Hologen AI, positions the company to potentially launch two wholly owned therapies within the next two years. A bolstered balance sheet following a $100 million equity offering extends its cash runway into the second half of 2028, significantly reducing near-term financing risk.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$19.00

Mean target$29.43

High · most bullish analyst$50.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects potential clinical trial delays or failures in the AQUAx2 study, regulatory hurdles for bota-vec filings, or manufacturing bottlenecks at the London and Shannon facilities, leading to accelerated cash burn and dilutive financing before 2028.

Base CaseCentral scenario

The base case assumes successful regulatory submissions for bota-vec in XLRP and positive pivotal Phase 2 AQUAx2 data for AAV2-hAQP1 in radiation-induced xerostomia by Q2 2027, leading to a BLA filing. Partnerships with Eli Lilly and Hologen AI continue to provide non-dilutive milestone funding, validating the platform's technology.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Wholly owned late-stage assets (bota-vec and AAV2-hAQP1) with near-term commercialization potential.
Strong validation and financial backing from global pharma leaders (Eli Lilly, Sanofi) and Hologen AI.
Proprietary end-to-end GMP manufacturing and QC infrastructure in London and Ireland.
Innovative synthetic riboswitch platform enabling precise, oral small-molecule control of gene expression.

Key Investment Risks

Clinical execution risk inherent in late-stage gene therapy trials.
Regulatory approval delays or strict labeling requirements from the FDA, MHRA, and EMA.
High operational cash burn typical of pre-commercial biotechnology companies.
Technical complexities in viral vector manufacturing and quality control.

Thesis Invalidation Triggers

Failure of the Phase 2 AQUAx2 trial to meet primary clinical endpoints.
Rejection or significant delays of bota-vec regulatory submissions by the FDA or MHRA.
Termination or material downgrading of the Eli Lilly or Hologen AI partnerships.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.